CX Institutional Purchases New Shares in Medpace Holdings, Inc. $MEDP

Key Points

• CX Institutional has acquired a new stake in Medpace Holdings, purchasing 4,443 shares valued at approximately $1.39 million in Q2.
• Medpace's stock received mixed analyst ratings, with price targets ranging from $270 to $510, and a consensus rating of Reduce.
• Insider selling activity has increased, with significant stock sales reported by CFO Kevin M. Brady and VP Susan E. Burwig, indicating a 66.67% decrease in Brady's position.

CX Institutional purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 4,443 shares of the company's stock, valued at approximately $1,394,000.

Other large investors have also added to or reduced their stakes in the company. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Brooklyn Investment Group grew its holdings in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after acquiring an additional 71 shares in the last quarter. Whittier Trust Co. grew its holdings in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after acquiring an additional 35 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Medpace during the 1st quarter worth $60,000. Finally, Assetmark Inc. grew its holdings in Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. UBS Group lowered shares of Medpace from a "neutral" rating to a "sell" rating and raised their price objective for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Truist Financial raised their price objective on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Mizuho raised their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Jefferies Financial Group raised their price target on shares of Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a research report on Tuesday, September 9th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, Medpace has a consensus rating of "Reduce" and a consensus price target of $422.27.

Medpace Stock Down 1.9%

Shares of NASDAQ:MEDP opened at $487.95 on Friday. The company has a market cap of $13.71 billion, a PE ratio of 36.28, a P/E/G ratio of 3.13 and a beta of 1.44. The company's 50-day moving average price is $461.13 and its 200 day moving average price is $359.58. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period in the previous year, the firm earned $2.75 EPS. Medpace's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares of the company's stock, valued at $2,725,380. The trade was a 66.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the transaction, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. This represents a 14.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 in the last three months. Insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.